在 SARS-CoV-2（新冠病毒）大流行期间勿忘耳毒性！
Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!
机构信息
ENT & Audiology Department, University Hospital of Ferrara, Ferrara, Italy.
Institute of Physiology and Pathology of Hearing, Warsaw, Poland.
出版信息
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420941754. doi: 10.1177/2058738420941754.
Abstract
Aim of this communication is to remind clinical professionals to be aware of ototoxic side effects of several specific drugs proposed for the treatment of the new virus SARS-CoV-2 (Covid-19). In particular, chloroquine and hydroxychloroquine, azithromycin, as well as antiviral drugs such as remdesivir, favipiravir and lopinavir can all present potential ototoxic side effects. The data in the literature do not offer specific information on their potential synergetic effects nor on their interactions.
摘要
本通讯旨在提醒临床专业人员注意几种用于治疗新型冠状病毒 SARS-CoV-2（Covid-19）的特定药物的耳毒性副作用。特别是氯喹和羟氯喹、阿奇霉素以及瑞德西韦、法匹拉韦和洛匹那韦等抗病毒药物都可能出现潜在的耳毒性副作用。文献中的数据并未提供关于它们潜在协同作用或相互作用的具体信息。
相似文献
1
Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!在 SARS-CoV-2（新冠病毒）大流行期间勿忘耳毒性！
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420941754. doi: 10.1177/2058738420941754.
2
Psychopharmacology of COVID-19.新型冠状病毒肺炎的精神药理学。
Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18.
3
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.SARS-CoV-2：洛匹那韦/利托那韦、达芦那韦/乌苯美司、羟氯喹、瑞德西韦、法匹拉韦等药物治疗新型冠状病毒的抗病毒治疗的最新报告。
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
4
Auditory Cinchonism in COVID Era.新冠疫情时代的听觉金鸡纳中毒
Ear Nose Throat J. 2020 Nov;99(9):597-598. doi: 10.1177/0145561320947255. Epub 2020 Aug 3.
5
Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.在 SARS-CoV-2（COVID-19）紧急情况下预防耳毒性。
J Glob Antimicrob Resist. 2020 Dec;23:263-264. doi: 10.1016/j.jgar.2020.09.030. Epub 2020 Oct 17.
6
Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2.抗SARS-CoV-2药物治疗的潜在促心律失常作用。
Arch Cardiol Mex. 2020;90(Supl):36-40. doi: 10.24875/ACM.M20000061.
7
QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.在新冠肺炎患者使用羟氯喹和/或阿奇霉素期间控制QT间期以预防尖端扭转型室速
Arq Bras Cardiol. 2020 Jun;114(6):1061-1066. doi: 10.36660/abc.20200389. Epub 2020 Jul 3.
8
Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.促进合理使用氯喹和羟氯喹治疗 2019 冠状病毒病（COVID-19）大流行的挑战与关切：及时综述。
J Toxicol Environ Health B Crit Rev. 2020 May 18;23(4):177-181. doi: 10.1080/10937404.2020.1752340. Epub 2020 Apr 12.
9
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1 April 2020].[新型冠状病毒肺炎大流行：对心血管系统的影响。2020年4月1日的数据]
Ann Cardiol Angeiol (Paris). 2020 May;69(3):107-114. doi: 10.1016/j.ancard.2020.04.001. Epub 2020 Apr 7.
10
Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.药物干预 COVID-19 相关不良反应的回顾：皮肤科医生的指南。
J Am Acad Dermatol. 2020 Dec;83(6):1738-1748. doi: 10.1016/j.jaad.2020.08.006. Epub 2020 Aug 7.
引用本文的文献
1
Persistent ENT Manifestations in Individuals who Recovered from COVID-19: A Systematic Review.新冠康复者的持续性耳鼻喉表现：一项系统综述
Int Arch Otorhinolaryngol. 2024 Mar 15;28(4):e697-e701. doi: 10.1055/s-0043-1777805. eCollection 2024 Oct.
2
Does coronavirus disease 2019 affect peripheral and central auditory systems? Matched group cross-sectional study and six-month follow up.2019 年冠状病毒病是否影响外周和中枢听觉系统？匹配组横断面研究和 6 个月随访。
J Laryngol Otol. 2024 Jun;138(6):601-607. doi: 10.1017/S0022215124000355. Epub 2024 Mar 8.
3
Impact of COVID-19 Medication (Favipiravir and Hydroxychloroquine) on High Frequency Hearing.新型冠状病毒肺炎药物（法匹拉韦和羟氯喹）对高频听力的影响
Indian J Otolaryngol Head Neck Surg. 2024 Feb;76(1):899-903. doi: 10.1007/s12070-023-04313-z. Epub 2023 Nov 7.
4
The Prevalence of Dizziness and Vertigo in COVID-19 Patients: A Systematic Review.新冠病毒感染患者中头晕和眩晕的患病率：一项系统综述
Brain Sci. 2022 Jul 20;12(7):948. doi: 10.3390/brainsci12070948.
5
ENT symptoms in acute COVID-19: a narrative review.急性新型冠状病毒肺炎的耳鼻喉症状：一项叙述性综述
Acta Otorhinolaryngol Ital. 2022 Apr;42(Suppl. 1):S14-S19. doi: 10.14639/0392-100X-suppl.1-42-2022-02.
6
Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review.用于治疗和预防新冠肺炎的药物及疫苗的不良听觉前庭效应：综述
Audiol Res. 2022 Apr 29;12(3):224-248. doi: 10.3390/audiolres12030025.
7
Blood Viscosity in COVID-19 Patients With Sudden Deafness.COVID-19 患者突发性聋的血液黏度。
Acta Otorrinolaringol Esp (Engl Ed). 2022 Mar-Apr;73(2):104-112. doi: 10.1016/j.otoeng.2022.02.004. Epub 2022 Feb 23.
8
The effects of SARS-CoV-2 on hearing thresholds in COVID-19 patients with non-hospitalized mild disease.新型冠状病毒 2 型对非住院轻症 COVID-19 患者听力阈值的影响。
Am J Otolaryngol. 2022 Mar-Apr;43(2):103320. doi: 10.1016/j.amjoto.2021.103320. Epub 2021 Dec 14.
9
Detecting Novel Ototoxins and Potentiation of Ototoxicity by Disease Settings.通过疾病状态检测新型耳毒素及耳毒性的增强作用。
Front Neurol. 2021 Aug 17;12:725566. doi: 10.3389/fneur.2021.725566. eCollection 2021.
10
[Blood viscosity in COVID-19 patients with sudden deafness].[新型冠状病毒肺炎合并突发性耳聋患者的血液黏度]
Acta Otorrinolaringol Esp. 2022 Mar-Apr;73(2):104-112. doi: 10.1016/j.otorri.2021.07.001. Epub 2021 Jul 15.
本文引用的文献
1
Audiological profile of asymptomatic Covid-19 PCR-positive cases.无症状新冠病毒 PCR 阳性病例的听力学特征。
Am J Otolaryngol. 2020 May-Jun;41(3):102483. doi: 10.1016/j.amjoto.2020.102483. Epub 2020 Apr 10.
2
Hearing loss and COVID-19: A note.听力损失与2019冠状病毒病：一则笔记
Am J Otolaryngol. 2020 May-Jun;41(3):102473. doi: 10.1016/j.amjoto.2020.102473. Epub 2020 Apr 2.
3
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.利巴韦林、瑞德西韦、索非布韦、加洛韦和替诺福韦对 SARS-CoV-2 RNA 依赖的 RNA 聚合酶（RdRp）的抑制作用：一项分子对接研究。
Life Sci. 2020 Jul 15;253:117592. doi: 10.1016/j.lfs.2020.117592. Epub 2020 Mar 25.
4
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.一项关于氯喹治疗 COVID-19 的疗效和安全性的系统评价。
J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.
5
Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review.接受铂类化疗的癌症幸存者受到耳毒性的影响及其对生活质量的影响：叙述性综合系统评价。
Int J Audiol. 2019 Nov;58(11):685-695. doi: 10.1080/14992027.2019.1660918. Epub 2019 Sep 23.
6
Viral causes of hearing loss: a review for hearing health professionals.病毒引起的听力损失：听力保健专业人员的综述。
Trends Hear. 2014 Jul 29;18:2331216514541361. doi: 10.1177/2331216514541361.
7
In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity.抗逆转录病毒药物的体外评估显示出耳毒性的可能性。
Hear Res. 2014 Apr;310:27-35. doi: 10.1016/j.heares.2014.01.005. Epub 2014 Jan 31.
8
Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide.致聋性、前庭症状和耳鸣的药物诱导作用：合理且最新的指南。
Eur Rev Med Pharmacol Sci. 2011 Jun;15(6):601-36.
9
Diabetes, cardiovascular risk factors and idiopathic sudden sensorineural hearing loss: a case-control study.糖尿病、心血管危险因素与特发性突发性感音神经性听力损失：一项病例对照研究。
Audiol Neurootol. 2010;15(2):111-5. doi: 10.1159/000231636. Epub 2009 Aug 4.
10
Chloroquine ototoxicity.氯喹耳毒性。
Clin Rheumatol. 2007 Nov;26(11):1809-10. doi: 10.1007/s10067-007-0662-6. Epub 2007 Jun 27.
Zotero 插件